Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy ; volume:22 ; number:1 ; day:11 ; month:3 ; year:2024 ; pages:1-16 ; date:12.2024
Cell communication and signaling ; 22, Heft 1 (11.3.2024), 1-16, 12.2024

Creator: Jin, Shengzhe
Wang, Hongfei
Li, Yang
Yang, Jingwen
Li, Beibei
Shi, Peishang
Zhang, Xiangrui
Zhou, Xiaowen
Zhou, Xiuman
Niu, Xiaoshuang
Wu, Menghan
Wu, Yahong
Zhai, Wenjie
Qi, Yuanming
Gao, Yanfeng
Zhao, Wenshan

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12964-024-01555-4

URN: urn:nbn:de:101:1-2405140752446.412714072733

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:56 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Jin, Shengzhe
Wang, Hongfei
Li, Yang
Yang, Jingwen
Li, Beibei
Shi, Peishang
Zhang, Xiangrui
Zhou, Xiaowen
Zhou, Xiuman
Niu, Xiaoshuang
Wu, Menghan
Wu, Yahong
Zhai, Wenjie
Qi, Yuanming
Gao, Yanfeng
Zhao, Wenshan
SpringerLink (Online service)

Other Objects (12)

Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 degradation pathway and immunotherapy for cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Clinical applications of PD-L1 bioassays for cancer immunotherapy

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 degradation pathway and immunotherapy for cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Clinical applications of PD-L1 bioassays for cancer immunotherapy

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 degradation pathway and immunotherapy for cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Clinical applications of PD-L1 bioassays for cancer immunotherapy

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 degradation pathway and immunotherapy for cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Clinical applications of PD-L1 bioassays for cancer immunotherapy

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 degradation pathway and immunotherapy for cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Clinical applications of PD-L1 bioassays for cancer immunotherapy

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 degradation pathway and immunotherapy for cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Clinical applications of PD-L1 bioassays for cancer immunotherapy

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Related objects

Reset password